BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

754 related articles for article (PubMed ID: 10928461)

  • 1. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study.
    Middeldorp S; Meijers JC; van den Ende AE; van Enk A; Bouma BN; Tans G; Rosing J; Prins MH; Büller HR
    Thromb Haemost; 2000 Jul; 84(1):4-8. PubMed ID: 10928461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways.
    Tans G; Curvers J; Middeldorp S; Thomassen MC; Meijers JC; Prins MH; Bouma BN; Büller HR; Rosing J
    Thromb Haemost; 2000 Jul; 84(1):15-21. PubMed ID: 10928463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.
    Kemmeren JM; Algra A; Meijers JC; Bouma BN; Grobbee DE
    Thromb Haemost; 2002 Feb; 87(2):199-205. PubMed ID: 11859850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
    Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
    Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renewed interest in haemostasis changes induced by oral contraceptives (OCs).
    Kluft C
    Thromb Haemost; 2000 Jul; 84(1):1-3. PubMed ID: 10928460
    [No Abstract]   [Full Text] [Related]  

  • 6. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of second- and third-generation oral contraceptives on fibrinolysis in the absence or presence of the factor V Leiden mutation.
    Kemmeren JM; Algra A; Meijers JC; Bouma BN; Grobbee DE
    Blood Coagul Fibrinolysis; 2002 Jul; 13(5):373-81. PubMed ID: 12138364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The APC-PCI concentration as an early marker of activation of blood coagulation: a study of women on combined oral contraceptives.
    Bremme K; Hamad RR; Berg E; Strandberg K; Stenflo J
    Thromb Res; 2012 Oct; 130(4):636-9. PubMed ID: 22154243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral contraceptives and blood coagulation.
    Bonnar J; Sabra AM
    J Reprod Med; 1986 Jun; 31(6 Suppl):551-6. PubMed ID: 2941571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study.
    Rosing J; Middeldorp S; Curvers J; Christella M; Thomassen LG; Nicolaes GA; Meijers JC; Bouma BN; Büller HR; Prins MH; Tans G
    Lancet; 1999 Dec; 354(9195):2036-40. PubMed ID: 10636369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood coagulation with a combination pill containing gestodene and ethinyl estradiol.
    Bonnar J; Daly L; Carroll E
    Int J Fertil; 1987; 32 Suppl():21-8. PubMed ID: 2906344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative metabolic effects of oral contraceptive preparations containing different progestagens. Effects of desogestrel + ethinylestradiol on the haemostatic balance.
    Rákóczi I; Gerö G; Demeter J; Gáti I
    Arzneimittelforschung; 1985; 35(3):630-3. PubMed ID: 3158320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
    Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
    Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hemostatic balance during treatment with the newest contraceptives].
    Petersen KR; Skouby SO; Sidelmann J; Jespersen J
    Ugeskr Laeger; 1994 Jan; 156(2):187-90. PubMed ID: 8296409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of coagulation in smoking and non-smoking women using a third-generation oral contraceptive containing desogestrel.
    Fruzzetti F; De Negri F; Morale M; Ricci C; Ferrini L; Bersi C; Genazzani AR; Carmassi F
    Eur J Contracept Reprod Health Care; 1999 Sep; 4(3):113-8. PubMed ID: 10574636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of two oral contraceptives, containing 30 or 20 microg of ethinyl estradiol in combination with gestodene, on blood coagulation and fibrinolysis in Brazilian women.
    Ferreira AC; Montes MB; Franceschini SA; Toloi MR
    Int J Fertil Womens Med; 2001; 46(5):265-70. PubMed ID: 11720199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young women.
    Petersen KR; Sidelmann J; Skouby SO; Jespersen J
    Am J Obstet Gynecol; 1993 Jan; 168(1 Pt 1):32-8. PubMed ID: 8420344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical review of a monophasic oral contraceptive containing desogestrel and ethinyl estradiol.
    Stone S
    Int J Fertil Menopausal Stud; 1993; 38 Suppl 3():117-21. PubMed ID: 8260969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 mu(g) ethinylestradiol and either 2 mg chlormadinone acetate or 150 mu(g) desogestrel.
    Winkler UH; Daume E; Sudik R; Oberhoff C; Bier U; Hallmann C; Andreas JO; Schindler AE
    Eur J Contracept Reprod Health Care; 1999 Sep; 4(3):145-54. PubMed ID: 10574640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.